JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simon, J. A.
Right arrow Articles by Perez-Perez, G. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simon, J. A.
Right arrow Articles by Perez-Perez, G. I.
Journal of the American College of Nutrition, Vol. 22, No. 4, 283-289 (2003)
Published by the American College of Nutrition


Original Research

Relation of Serum Ascorbic Acid to Helicobacter pylori Serology in US Adults: the Third National Health and Nutrition Examination Survey

Joel A. Simon, MD, MPH, FACN, Esther S. Hudes, PhD, MPH and Guillermo I. Perez-Perez, DSc

General Internal Medicine Section, Medical Service, San Francisco Veterans Affairs Medical Center, (J.A.S.), New York, New York
Department of Epidemiology and Biostatistics (J.A.S., E.S.H.), New York, New York
University of California, San Francisco, California, Departments of Medicine and Microbiology, New York University School of Medicine, New York, New York (G.I.P.-P.)

Address reprint requests to: Dr. Joel A. Simon, General Internal Medicine (111A1), San Francisco VA Medical Center, 4150 Clement Street, San Francisco, California, 94121. E-mail: jasimon{at}itsa.ucsf.edu


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Purpose: To examine the relation between serum ascorbic acid and Helicobacter pylori serology from a probability sample of US adults.

Subjects and Methods: Data from 6,746 adults (ages 20 to 90 years) enrolled in the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994 were analyzed. Multiple logistic regression models were examined taking into account sample weights and the complex survey design of NHANES III, and controlling for the effects of potential confounders. Because race appeared to modify the association between serum ascorbic acid and seropositivity to H. pylori, we conducted the analyses stratified by race.

Results: A total of 2,189 adults (32%) had a positive serology for H. pylori, and, of these, 1,175 (54%) were positive for the CagA antigen. Among whites, a 0.50 mg/dL increase in serum ascorbic acid level was associated with decreased seroprevalence of H. pylori (Odds Ratio (OR) = 0.89, 95% confidence interval (CI) CI 0.82–0.96, p < 0.01). In analyses that controlled for seroprevalence of H. pylori, a 0.50 mg/dL increase in serum ascorbic acid level among whites was independently associated with a decreased seroprevalence of the pathogenic cagA-positive strain of H. pylori (OR = 0.31, 95% CI 0.12–0.79, p < 0.05). Serum ascorbic acid levels were not significantly associated with H. pylori serology among non-whites (all p > 0.05).

Conclusions: Higher serum levels of ascorbic acid were associated with a decreased seroprevalence of H. pylori and of the pathogenic cagA-positive strain of H. pylori among whites. If these associations are related causally and are not the result of residual confounding by factors such as socioeconomic status, ascorbic acid may affect the risk of H. pylori infection and in turn, the risk for peptic ulcer disease and gastric cancer among white Americans.

Key words: ascorbic acid, Helicobacter pylori, vitamin C


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 ACKNOWLEDGMENTS
 REFERENCES
 
There is a long history relating ascorbic acid status to gastritis [1,2], ulcer disease [36] and risk for gastric cancer [79]. Epidemiologic reviews have also linked lower dietary ascorbic acid consumption with an increased risk for gastric cancer [1012]. It is now known that chronic infection with Helicobacter pylori, and especially the strains encoding the cytotoxin-associated gene (cagA), are important risk factors for peptic ulcer disease [13,14] and gastric cancer [1517]. In one animal study, increased consumption of ascorbic acid inhibited the growth of H. pylori [18]. Although H. pylori has been reported to reversibly lower gastric juice ascorbic acid [19–23], plasma ascorbic acid levels do not appear to change after successful treatment and eradication of H. pylori [1921]. Most reports have not found an association between plasma ascorbic acid concentrations and H. pylori [19,21,23,24]. However, all but one of these studies [24] was conducted among a small number of subjects. To our knowledge, there are no published reports examining the relation between blood ascorbic acid status and H. pylori among a large population-based sample of Americans.

To ascertain whether serum ascorbic acid is associated with serologic evidence of infection with H. pylori and particularly with strains expressing the cagA virulence factor, we analyzed data collected from the Third National Health and Nutrition Examination Survey (NHANES III) that included serum ascorbic acid levels and H. pylori serology on more than 6,000 American adults.


    METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Study Population
NHANES III was a national probability survey of Americans conducted between 1988 and 1994 that employed a stratified, cluster sampling design to over sample populations of special interest [25]. Participants, two months to 90 years of age, were enrolled, interviewed and examined by study personnel [25]. NHANES III recorded subjects >90 years as being 90 years old. For these analyses, participants were excluded if there were missing data on variables judged to be potential predictors of H. pylori colonization. We restricted our analyses to adults with values for serum ascorbic acid and excluded 19 participants with serum ascorbic acid levels of questionable validity (i.e., >3.0 mg/dL) [26]. After these exclusions, complete data were available from 6,746 participants between the ages of 20 and 90 years for these analyses. Comparing included and excluded participants revealed no statistically significant differences in age, race, gender, level of education or level of physical activity (all p > 0.21).

NHANES III data were collected in two phases. The first phase was conducted from October 18, 1988 through October 24, 1991, and the second phase was conducted between September 20, 1991 and October 15, 1994 [25]. Only serum specimens collected in Phase 1 were assayed for evidence of seropositivity to H. pylori.

Measurements
NHANES III questionnaire data included self-reported age, race, gender, annual household income, history of smoking, level of physical activity and medication use [25]. Body mass index (kg/m2) was calculated from weight and height data recorded during the physical examination. Dietary intake estimates were based on a 24-hour diet recall. The questionnaires and examination procedures used in NHANES III have been described elsewhere in detail [25].

From stored serum samples among Phase I participants, H. pylori serology was performed using a commercial IgG ELISA assay (Wampole Laboratories, Cranbury, NJ) [27]. In brief, each 96-well plate contained the manufacturer’s three cutoff controls (negative, high positive and low positive) in addition to three positive and two negative controls. For each specimen, an immune status ratio (ISR) was calculated by dividing the specimen optical density by the mean optical density of the three cutoff controls. Specimens were considered negative if the ISR was 0–0.90, equivocal if the ISR was 0.91–1.09 and positive if the ISR was >=1.10. This assay has demonstrated a sensitivity of 91 percent and specificity of 96 percent [27]. In additional analyses, there was little overall disagreement (3%) between duplicate tests for overall H. pylori serology.

Using stored serum specimens, the presence of specific serum antibodies to H. pylori CagA protein was determined, as reported previously [16]. As part of another research project, the assays were performed by a team of investigators that included one of the authors of this paper (G.I.P.-P.) [27]. We used an ELISA that has been previously validated with a sensitivity and specificity of 94.4 percent and 92.5 percent, respectively [16]. We used a recombinant CagA antigen provided by Oravax, Cambridge MA. The results of each sample were expressed as the ratio of the optical density value of the sample to the four positive controls (ODR). The absorbance index cutoff value for a positive test was established as an ODR >0.35, as previously described [28]. Of the 4557 participants who were H. pylori negative, 461 had a positive serologic test for CagA antigen, i.e., an ostensible false positive rate of 10.1%. In additional recently published analyses that examined the test reliability of the serologic assays, repeat CagA serologies were performed among participants who tested positive, equivocal and negative to the CagA subtype [29]. Reproducibility for the CagA antibody test was 93.4% if the initial H. pylori test was positive, 91.1% if it was equivocal and 86.3% if it was negative [29]. Serum ascorbic acid levels were measured at the Centers for Disease Control and Prevention in Atlanta, GA by high performance liquid chromatography [30] and ranged from 0.0 mg/dL to an upper cut point of 3.00 mg/dL. Specimens were prepared from fresh serum and immediately mixed with metaphosphoric acid. The samples were then centrifuged, frozen at -70°C and shipped on dry ice by overnight mail to the CDC for analysis [30].

Statistical Analysis
We examined the distribution of ascorbic acid levels and other variables of interest using complex survey design and Phase I sample weights. Phase I sample design and sample weights were used because information on H. pylori serology was collected only during Phase I of the study. Means of continuous variables were compared using linear regression for weighted survey data. Proportions for categorical variables were compared using cross tabulation for weighted survey data with an F statistic.

We used age-adjusted and multivariate logistic regression, taking into account sampling weights and the complex survey design of NHANES III, to examine the relation of serum ascorbic acid to H. pylori serology. Because we identified a cross-product interaction between serum ascorbic acid, race and H. pylori serology (p < 0.05), we conducted our analyses stratified by race (white vs. non-white). Multivariate models controlled for the effects of self-reported age (years), gender (male vs. female), level of education (years completed), cigarette smoking (never, past, current), alcohol intake (grams per day), usual level of physical activity (self-reported as "less active," "about the same," and "more active" than peers) and use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs). We selected these variables as potential confounders based on their previously reported association with either serum ascorbic acid, peptic ulcer disease or H. pylori infection. Participants whose H. pylori serology was equivocal were included with seronegative participants for all analyses [27]. We also examined the relation of serum ascorbic acid to H. pylori’s CagA serology status in age- and multivariate-adjusted logistic regression models. The age-adjusted and the multivariate models examining CagA serology controlled for the same variables as the H. pylori serology analyses, but additionally controlled for H. pylori serology status. We also analyzed the relation between serum ascorbic acid and seropositivity to H. pylori by quartile of serum ascorbic acid. To test for monotonic trends across quartiles, we assigned each participant the median value for the category and then analyzed these values as a continuous variable.

Analyses were performed using Stata software that included commands for the analysis of complex survey data [31]. Stata uses the Taylor linearization method to estimate standard errors from complex surveys. We calculated odds ratios (OR) and 95 percent confidence intervals (CI) to examine the association of serum ascorbic acid level to H. pylori seropositivity. We considered two-tailed p values of <0.05 to be statistically significant.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 ACKNOWLEDGMENTS
 REFERENCES
 
The baseline characteristics of 6,746 adult participants enrolled in NHANES III with complete data available for these analysis are presented in Table 1. A total of 2,189 participants (32%) had positive serologic results for H. pylori, and, of those with positive serology, 1,175 (54%) were positive for the cagA strain. The gender, percentage of current cigarette smokers and self-reported use of non-steroidal anti-inflammatory drugs among participants who were seropositive and seronegative for H. pylori were similar. However, some other variables differed by seropositivity status. Serum ascorbic acid levels were consistent with normal levels for this micronutrient in both groups [26], although mean levels were, on average, slightly lower among seropositive participants.


View this table:
[in this window]
[in a new window]
 
Table 1. Characteristics of 6,746 Participants 20 Years of Age or Older Enrolled in the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994

 
Among whites, age-adjusted and multivariate models revealed that serum ascorbic acid levels were inversely associated with seroprevalence of H. pylori (Table 2). The odds ratio was slightly attenuated after multivariable adjustment, suggesting the presence of some confounding; each 0.50 mg/dL increase in serum ascorbic acid levels was independently associated with a decrease in seropositivity (OR = 0.89, 95% CI 0.82 to 0.96, p < 0.01). In the multivariate models, body mass index, physical activity, alcohol consumption and cigarette smoking were not significantly associated with H. pylori seropositivity (all p > 0.08). However, younger age, higher level of education, use of aspirin and NSAIDs were all associated with decreased seropositivity to H. pylori among whites (all p <= 0.03). Among non-whites, serum ascorbic acid was not significantly associated with H. pylori seropositivity in either of the models (both p > 0.87). Similar to the analyses among whites, younger age, aspirin use and higher level of education were associated with a decreased seropositivity to H. pylori (both p <= 0.03).


View this table:
[in this window]
[in a new window]
 
Table 2. The Relation of Serum Ascorbic Acid Level (Per 0.5 mg/dL Increase) to Seropositivity to Helicobacter pylori among 5,836 White Participants and 910 Non-White Participants 20 Years of Age or Older Enrolled in the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994 Stratified by Race

 
In models that examined the relation between serum ascorbic acid and seroprevalence of the cagA-positive strain of H. pylori among whites, a 0.5 mg/dL increase in serum ascorbic acid was associated with a large decrease in seropositivity (OR = 0.31, 95% CI 0.12 to 0.79, p = 0.02) (Table 2). Although the direction of this relation was similar among non-whites, the confidence intervals where wide, and the association was not statistically significant (OR = 0.26, 95% CI 0.01 to 5.14, p = 0.36).

Additional models that analyzed the relation of serum ascorbic acid (by quartile) as a predictor of H. pylori seropositivity were examined (Table 3). For whites, there was a trend for seropositivity to H. pylori to decrease as serum ascorbic acid increased (p for trend = 0.08) that was not observed among non-whites (p = 0.81).


View this table:
[in this window]
[in a new window]
 
Table 3. The Relation of Serum Ascorbic Acid Level by Quartile to Seropositivity to Helicobacter pylori among 6,746 Participants 20 Years of Age or Older Enrolled in the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994 Stratified by Race

 
We re-examined all the models after excluding 26 participants with serum ascorbic acid levels reported as zero. The result were virtually identical after these exclusions.


    DISCUSSION
 
Our principal finding was that serum ascorbic acid was inversely related to seroprevalence of both H. pylori and the pathogenic cagA-positive strain of H. pylori among whites enrolled in NHANES III. The associations remained statistically significant after multivariable adjustment. Although we did not observe a significant association between serum ascorbic acid and H. pylori serology among non-whites, the magnitude of the inverse association between serum ascorbic acid and CagA seroprevalence was similar for both whites and non-whites. We cannot exclude the possibility that the non-significant association between serum ascorbic acid and H. pylori CagA serology among non-whites may reflect inadequate statistical power. However, black-white differences in H. pylori infection rates [27,32,33] or in gastric ascorbic acid concentrations among infected blacks and whites have been reported previously [20]. Blacks have higher H. pylori infection rates than whites [27,32,33], and seropositive blacks have been reported to have lower levels of gastric ascorbic acid than whites [20]. Hence, the difference that we observed between whites and non-whites in the relation of serum ascorbic acid to H. pylori seropositivity may reflect true biologic variability.

Because of the cross-sectional design of NHANES III, we cannot be certain that colonization with or gastric inflammation caused by H. pylori does not lower serum ascorbic acid levels directly (by increasing ascorbic acid turnover) or indirectly (by causing a change in the pattern of consumption of ascorbic acid-containing foods or a change in the absorption of ascorbic acid) [34]. It has been reported, however, that ascorbic acid inhibits the growth of H. pylori in animal models [18,35]. It is therefore possible that higher serum levels of ascorbic acid may decrease the risk of H. pylori infection, perhaps by affecting gastric juice ascorbic acid concentrations. This possibility is somewhat increased by reports which indicate that the successful treatment and eradication of H. pylori does not appear to affect plasma ascorbic acid levels [1921]. That is, if serum ascorbic acid levels were lowered by H. pylori infection thereby producing the inverse relation that we observed, it might be expected that treatment for H. pylori would result in increased post-treatment blood ascorbic acid levels, which has not been reported. Consistent with our findings, Fontham et al. [32] and Goodman et al. [36] have reported that adequate vitamin C intake was associated with a decreased prevalence of H. pylori infection.

In contrast to our findings, other investigators have not reported an association between plasma ascorbic acid and H. pylori seropositivity among predominantly white study subjects [19,21,23,24]. Four of these studies [19,21,23,37] were small, enrolling a convenience sample of between 29 and 69 participants with dyspepsia or ulcer disease. The larger EUROGAST study, which also examined the cross-sectional relation between plasma ascorbic acid and H. pylori infection and reported no significant association, enrolled 1404 participants at nine clinical centers, including one in the US [24]. This study, however, did note that H. pylori seropositive participants had slightly lower plasma ascorbic acid levels compared with seronegative participants (p = 0.20). Our probability sample of Americans analyzed in NHANES III was almost fivefold greater in size compared with the EUROGAST study; consequently, we had considerably greater statistical power to detect an association. We are unaware of prior studies that may have examined the relation of blood ascorbic acid levels to CagA seropositivity. Seropositivity to the CagA antigen of H. pylori has been associated with increased pathogenicity and risk for gastric cancer [16,38].

H. pylori is now recognized as an important cause of peptic ulcer disease and gastric cancer [15,17,39]. The epidemiologic evidence also suggests that dietary ascorbic acid may decrease the risk of gastric cancer [1012,40]. Hayat and Everett [41] hypothesized that ascorbic acid may be a factor in the causal pathway that links H. pylori infection with gastric cancer. From our study, we cannot reach such a conclusion, but our findings do confirm that serum ascorbic acid and H. pylori are associated inversely and that the association is independent of a number of other factors for which we were able to control. If the associations we observed are not the result of residual confounding, it would suggest two possibilities: that higher levels of ascorbic acid may have the potential to decrease the risk of peptic ulcer disease and perhaps gastric cancer and that H. pylori seropositive individuals may need to increase their intake of dietary ascorbic acid to prevent an H. pylori-associated decrease in serum ascorbic acid levels. Because over 50% of older Americans have serologic evidence of H. pylori infection [27], our findings could have public health significance.

Our study was limited by several factors. NHANES III did not measure gastric juice ascorbic acid levels; hence, we are unable to comment on the relation of gastric juice ascorbic acid to H. pylori seropositivity. Although it is biologically plausible that ascorbic acid may affect the risk of infection with H. pylori, we cannot exclude the possibility that infection with H. pylori lowers serum ascorbic acid levels. There likely was some degree of measurement error regarding the determination of serum ascorbic acid levels and the classification of H. pylori status. However, such measurement error, if non-differential, would tend to result in a decreased probability of being able to detect positive findings and an attenuation of the magnitude of the relation. Although we adjusted for differences in level of education (a proxy for socioeconomic status), physical activity, cigarette smoking and alcohol consumption, it is nevertheless possible that the effects of such factors were only partially accounted for in the multivariable modeling, i.e., our findings may have resulted from residual confounding. Such concern is warranted for socioeconomic status, especially during childhood, which is associated with both poorer nutrition and H. pylori infection. Therefore, we cannot be certain that differences in serum ascorbic acid level preceded infection with H. pylori, and inferences regarding causality should not be made based on the results of this study.

In conclusion, serum ascorbic acid is significantly correlated with seropositivity to both H. pylori and to the pathogenic cagA-positive strain of H. pylori among white Americans. To our knowledge, this report is the first population-based study of Americans to report such associations. If these findings are confirmed by other investigators and are linked causally, higher intakes of ascorbic acid may be a protective factor in the prevention of H. pylori infection.


    ACKNOWLEDGMENTS
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 ACKNOWLEDGMENTS
 REFERENCES
 
This study was supported by a donation from Roche Vitamins, Inc. and Public Health Service grant HL53479.

Received June 21, 2002. Accepted December 12, 2002.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 METHODS
 RESULTS
 ACKNOWLEDGMENTS
 REFERENCES
 

  1. Wood P: A case of adult scurvy. Lancetii :1405 –1406,1935 .
  2. Ludden JB, Flexner J, Wright IS: Studies on ascorbic acid deficiency in gastric diseases: incidence, diagnosis and treatment. Am J Dig Dis8 :249 –252,1941 .
  3. Davidson PB: The development of deficiency disease during therapeutic diets. JAMA90 :1014 –1015,1928 .
  4. Archer HE, Graham G: The subscurvy state in relation to gastric and duodenal ulcer. Lancetii :364 –366,1936 .
  5. Ingalls TH, Warren HA: Asymptomatic scurvy: its relation to wound healing and its incidence in patients with peptic ulcer. N Engl J Med217 :443 –446,1937 .
  6. Cohen MM, Duncan AM: Ascorbic acid nutrition in gastroduodenal disorders. Br Med J4 :516 –518,1967 .
  7. Bjelke E: Epidemiologic studies of cancer of the stomach, colon, and rectum with special emphasis on the role of diet. Scand J Gastroenterol31(Suppl) :1 –235,1974 .
  8. Correa P, Fontham E, Pickle LW, Chen VLY, Haenszel W: Dietary determinants of gastric cancer in south Louisiana inhabitants. J Natl Cancer Inst75 :645 –654,1985 .
  9. Risch HA, Jain M, Choi NW, Fodor JG, Pfeiffer CJ, Howe GR, Harrison LW, Craib KJP, Miller AB: Dietary factors and the incidence of cancer of the stomach: Am J Epidemiol122 :947 –959,1985 .[Abstract/Free Full Text]
  10. Block G: Epidemiologic evidence regarding vitamin C and cancer. Am J Clin Nutr54 :1310S –1314S,1991 .[Abstract/Free Full Text]
  11. Cohen M, Bhagavan HN: Ascorbic acid and gastrointestinal cancer. J Am Coll Nutr14 :565 –578,1995 .[Abstract]
  12. Flagg EW, Coates RJ, Greenberg RS: Epidemiologic studies of antioxidants and cancer in humans. J Am Coll Nutr14 :419 –427,1995 .[Abstract]
  13. NIH Consensus Conference on Helicobacter pylori in Peptic Ulcer Disease: Helicobacter pylori in peptic ulcer disease. JAMA272 :65 –69,1994 .[Medline]
  14. Covacci A, Censini S, Bugnoili M, Petracca R, Burroni D, Macchia G, Massone A, Papini E, Xiang Z, Figura N, Rappuoli R: Molecular characteristics of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci90 :5791 –5795,1993 .[Abstract/Free Full Text]
  15. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobactor pylori infection and risk of gastric carcinoma. N Engl J Med325 :1127 –1131,1991 .[Abstract]
  16. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A: Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk for developing adenocarcinoma of the stomach. Cancer Res55 :2111 –2115,1995 .[Abstract/Free Full Text]
  17. Helicobacter and Cancer Collaborative Group: Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut49 :347 –353,2001 .[Abstract/Free Full Text]
  18. Zhang H-M, Wakisaka N, Maeda O, Yamamoto T: Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: Helicobacter pylori. Cancer80 :1897 –1903,1997 .[Medline]
  19. Sobala GM, Schorah CJ, Shires S, Lynch DAF, Gallacher B, Dixon MF, Axon ATR: Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut34 :1038 –1041,1993 .[Abstract/Free Full Text]
  20. Ruiz B, Carlton Rood J, Fontham ETH, Malcom GT, Hunter FM, Sobhan M, Johnson WD, Correa P: Vitamin C concentration in gastric juice before and after anti-Helicobacter pylori treatment. Am J Gastroenterol89 :533 –539,1994 .[Medline]
  21. Banerjee S, Hawksby C, Miller S, Dahill S, Beattie AD, McColl KEL: Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid. Gut35 :317 –322,1994 .[Abstract/Free Full Text]
  22. Fraser AG, Woollard GA: Helicobacter pylori, peptic ulcer and non-ulcer dyspepsia: gastric juice ascorbic acid is related to Helicobacter pylori infection but not ethnicity. J Gastroenterol Hepatol14 :1070 –1073,1999 .[Medline]
  23. Rokkas T, Liatsos C, Petridou E, Papatheodorou G, Karameris A, Ladas SD, Raptis SA: Relationship of Helicobacter pylori CagA(+) status to gastric juice vitamin C levels. Eur J Clin Invest29 :56 –62,1999 .[Medline]
  24. Webb PM, Bates CJ, Palli D, Forman D: Gastric cancer, gastritis and plasma vitamin C: results from an international correlation and cross-sectional study. Intl J Cancer73 :684 –689,1997 .[Medline]
  25. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. National Center for Health Statistics. Vital Health Stat 1(32).1994 .
  26. Simon JA: Vitamin C and cardiovascular disease: a review. J Am Coll Nutr11 :107 –125,1992 .[Abstract]
  27. Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G: Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis181 :1359 –1363,2000 .[Medline]
  28. Kuipers EJ, Perez-Perez GI, Meuwissen SB, Blaser MJ: Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst87 :1777 –1780,1995 .[Abstract/Free Full Text]
  29. Everhart JE, Kruszon-Moran D, Perez-Perez G: Reliability of Helicobacter pylori and CagA serological assays. Clin Diag Lab Immunol9 :412 –416,2002 .[Abstract/Free Full Text]
  30. Gunter EW, Lewis BG, Koncikowski SM: "Laboratory Procedures Used for the Third Health and Nutrition Examination Survey (NHANES III), 1988–1994." Atlanta: US Dept of Health and Human Services, PHS, Centers for Disease Control and Prevention, Center for Environmental Health; Hyattsville, MD: National Center for Health Statistics,1996 .
  31. Stata Corp.2001 . Stata Statistical Software: Release 7.0; College Station, TX: Stata Corporation.
  32. Fontham ETH, Ruiz B, Perez A, Hunter F, Correa P: Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol90 :1094 –1101,1995 .[Medline]
  33. Staat MA, Kruszon-Moran D, McQuillan GM, Kaslow RA: A population-based serologic survey of Helicobacter pylori infection on children and adolescents in the United States. J Infect Dis174 :1120 –1123,1996 .[Medline]
  34. Woodward M, Tunstall-Pedoe H, McColl K: Helicobacter pylori infection reduces systemic availability of dietary vitamin C. Eur J Gastroenterol Hepatol13 :233 –237,2001 .[Medline]
  35. Sjunnesson H, Sturegård E, Willén R, Wadström T: High intake of selenium, beta carotene, and vitamins A, C, and E reduces growth of Helicobacter pylori in the guinea pig. Comp Med51 :418 –423,2001 .[Medline]
  36. Goodman KJ, Correa P, Tengana Aux HJ, DeLany JP, Collazos T: Nutritional factors and Helicobacter pylori infection in Colombian children. J Pediatr Gastroenterol Nutr25 :507 –515,1997 .[Medline]
  37. Phull PS, Price AB, Thorniley MS, Green CJ, Jacyna MR: Plasma free radical activity and antioxidant vitamin levels in dyspeptic patients: correlation with smoking and Helicobacter pylori infection. Eur J Gastroenterol Hepatol10 :573 –578,1998 .[Medline]
  38. Parsonnet J, Friedman GD, Orentreich N, Vogelman H: Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut40 :297 –301,1997 .[Abstract/Free Full Text]
  39. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med345 :784 –789,2001 .[Abstract/Free Full Text]
  40. Ekström AM, Serafini M, Nyrén O, Hansson L-E, Ye W, Wolk A: Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Intl J Cancer87 :133 –140,2000 .[Medline]
  41. Hayat M, Everett S: Lymphocytic gastritis, Helicobacter pylori, and gastric cancer: is vitamin C the common link? Nutr15 :402 –403,1999 .



This article has been cited by other articles:


Home page
Am J EpidemiolHome page
V. M. Cardenas, Z. D. Mulla, M. Ortiz, and D. Y. Graham
Iron Deficiency and Helicobacter pylori Infection in the United States
Am. J. Epidemiol., January 15, 2006; 163(2): 127 - 134.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simon, J. A.
Right arrow Articles by Perez-Perez, G. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simon, J. A.
Right arrow Articles by Perez-Perez, G. I.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS